Pharmacoepidemiological Evaluation in Prostate Cancer-Common Pitfalls and How to Avoid Them

Area of Science:

• Pharmacoepidemiology
• Oncology
• Drug Safety

Background:

• Pharmacoepidemiologic research evaluates the real-world impact of common medications (e.g., cholesterol-lowering, antidiabetic drugs) on prostate cancer risk and mortality.
• This research is vital for understanding drug effects in clinical practice.
• However, these studies are susceptible to biases stemming from systematic differences between drug users and non-users.

Purpose of the Study:

• To identify and describe common biases encountered in pharmacoepidemiologic studies.
• To provide methods for mitigating these biases, specifically within prostate cancer research.
• To enhance the estimation of causality between medication use and cancer outcomes.

Main Methods:

• Review and description of common biases in pharmacoepidemiologic research.
• Discussion of mitigation strategies for identified biases.
• Focus on the context of prostate cancer risk and mortality.

Main Results:

• Identification of multiple sources of bias in pharmacoepidemiologic studies, particularly related to user/non-user differences.
• Potential for biased results and erroneous conclusions if biases are not controlled.
• Listing of methods to improve the quality and causal inference of future research.

Conclusions:

• Addressing biases is essential for the validity of pharmacoepidemiologic research on drug effects and cancer.
• Implementing bias mitigation strategies can improve the accuracy of real-world drug effect estimations.
• This work aims to guide future research towards more reliable conclusions on medication use and prostate cancer outcomes.